MX2015016715A - Agonistas del receptor de la vitamina d para tratar enfermedades que afectan a la actividad de cxcl12. - Google Patents
Agonistas del receptor de la vitamina d para tratar enfermedades que afectan a la actividad de cxcl12.Info
- Publication number
- MX2015016715A MX2015016715A MX2015016715A MX2015016715A MX2015016715A MX 2015016715 A MX2015016715 A MX 2015016715A MX 2015016715 A MX2015016715 A MX 2015016715A MX 2015016715 A MX2015016715 A MX 2015016715A MX 2015016715 A MX2015016715 A MX 2015016715A
- Authority
- MX
- Mexico
- Prior art keywords
- vitamin
- receptor agonists
- treat diseases
- diseases involving
- agonists
- Prior art date
Links
- 239000000018 receptor agonist Substances 0.000 title abstract 3
- 229940044601 receptor agonist Drugs 0.000 title abstract 3
- 102000009310 vitamin D receptors Human genes 0.000 title abstract 3
- 108050000156 vitamin D receptors Proteins 0.000 title abstract 3
- 101150067717 CXCL12 gene Proteins 0.000 title 1
- 201000010099 disease Diseases 0.000 title 1
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 title 1
- 229930003316 Vitamin D Natural products 0.000 abstract 3
- QYSXJUFSXHHAJI-XFEUOLMDSA-N Vitamin D3 Natural products C1(/[C@@H]2CC[C@@H]([C@]2(CCC1)C)[C@H](C)CCCC(C)C)=C/C=C1\C[C@@H](O)CCC1=C QYSXJUFSXHHAJI-XFEUOLMDSA-N 0.000 abstract 3
- 235000019166 vitamin D Nutrition 0.000 abstract 3
- 239000011710 vitamin D Substances 0.000 abstract 3
- 150000003710 vitamin D derivatives Chemical class 0.000 abstract 3
- 229940046008 vitamin d Drugs 0.000 abstract 3
- 108010088406 Glucagon-Like Peptides Proteins 0.000 abstract 2
- 206010033645 Pancreatitis Diseases 0.000 abstract 2
- 239000000556 agonist Substances 0.000 abstract 2
- 239000002243 precursor Substances 0.000 abstract 2
- 108010011459 Exenatide Proteins 0.000 abstract 1
- HTQBXNHDCUEHJF-XWLPCZSASA-N Exenatide Chemical compound C([C@@H](C(=O)N[C@@H]([C@@H](C)CC)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](CC=1C2=CC=CC=C2NC=1)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](CC(N)=O)C(=O)NCC(=O)NCC(=O)N1[C@@H](CCC1)C(=O)N[C@@H](CO)C(=O)N[C@@H](CO)C(=O)NCC(=O)N[C@@H](C)C(=O)N1[C@@H](CCC1)C(=O)N1[C@@H](CCC1)C(=O)N1[C@@H](CCC1)C(=O)N[C@@H](CO)C(N)=O)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CCCNC(N)=N)NC(=O)[C@@H](NC(=O)[C@H](C)NC(=O)[C@H](CCC(O)=O)NC(=O)[C@H](CCC(O)=O)NC(=O)[C@H](CCC(O)=O)NC(=O)[C@H](CCSC)NC(=O)[C@H](CCC(N)=O)NC(=O)[C@H](CCCCN)NC(=O)[C@H](CO)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CC(O)=O)NC(=O)[C@H](CO)NC(=O)[C@@H](NC(=O)[C@H](CC=1C=CC=CC=1)NC(=O)[C@@H](NC(=O)CNC(=O)[C@H](CCC(O)=O)NC(=O)CNC(=O)[C@@H](N)CC=1NC=NC=1)[C@@H](C)O)[C@@H](C)O)C(C)C)C1=CC=CC=C1 HTQBXNHDCUEHJF-XWLPCZSASA-N 0.000 abstract 1
- 102100025101 GATA-type zinc finger protein 1 Human genes 0.000 abstract 1
- 101710198884 GATA-type zinc finger protein 1 Proteins 0.000 abstract 1
- DTHNMHAUYICORS-KTKZVXAJSA-N Glucagon-like peptide 1 Chemical compound C([C@@H](C(=O)N[C@@H]([C@@H](C)CC)C(=O)N[C@@H](C)C(=O)N[C@@H](CC=1C2=CC=CC=C2NC=1)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](C(C)C)C(=O)N[C@@H](CCCCN)C(=O)NCC(=O)N[C@@H](CCCNC(N)=N)C(N)=O)NC(=O)[C@H](CCC(O)=O)NC(=O)[C@H](CCCCN)NC(=O)[C@H](C)NC(=O)[C@H](C)NC(=O)[C@H](CCC(N)=O)NC(=O)CNC(=O)[C@H](CCC(O)=O)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CC=1C=CC(O)=CC=1)NC(=O)[C@H](CO)NC(=O)[C@H](CO)NC(=O)[C@@H](NC(=O)[C@H](CC(O)=O)NC(=O)[C@H](CO)NC(=O)[C@@H](NC(=O)[C@H](CC=1C=CC=CC=1)NC(=O)[C@@H](NC(=O)CNC(=O)[C@H](CCC(O)=O)NC(=O)[C@H](C)NC(=O)[C@@H](N)CC=1N=CNC=1)[C@@H](C)O)[C@@H](C)O)C(C)C)C1=CC=CC=C1 DTHNMHAUYICORS-KTKZVXAJSA-N 0.000 abstract 1
- 229940084891 byetta Drugs 0.000 abstract 1
- 206010012601 diabetes mellitus Diseases 0.000 abstract 1
- 208000001072 type 2 diabetes mellitus Diseases 0.000 abstract 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/59—Compounds containing 9, 10- seco- cyclopenta[a]hydrophenanthrene ring systems
- A61K31/593—9,10-Secocholestane derivatives, e.g. cholecalciferol, i.e. vitamin D3
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
- A61K31/513—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim having oxo groups directly attached to the heterocyclic ring, e.g. cytosine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
- A61K31/517—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with carbocyclic ring systems, e.g. quinazoline, perimidine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/59—Compounds containing 9, 10- seco- cyclopenta[a]hydrophenanthrene ring systems
- A61K31/592—9,10-Secoergostane derivatives, e.g. ergocalciferol, i.e. vitamin D2
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/70—Carbohydrates; Sugars; Derivatives thereof
- A61K31/7042—Compounds having saccharide radicals and heterocyclic rings
- A61K31/7052—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides
- A61K31/706—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom
- A61K31/7064—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom containing condensed or non-condensed pyrimidines
- A61K31/7068—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom containing condensed or non-condensed pyrimidines having oxo groups directly attached to the pyrimidine ring, e.g. cytidine, cytidylic acid
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
- A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
- A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
- A61K47/62—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being a protein, peptide or polyamino acid
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
- A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
- A61K47/68—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment
- A61K47/6835—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment the modifying agent being an antibody or an immunoglobulin bearing at least one antigen-binding site
- A61K47/6849—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment the modifying agent being an antibody or an immunoglobulin bearing at least one antigen-binding site the antibody targeting a receptor, a cell surface antigen or a cell surface determinant
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/18—Drugs for disorders of the alimentary tract or the digestive system for pancreatic disorders, e.g. pancreatic enzymes
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
- A61P13/08—Drugs for disorders of the urinary system of the prostate
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
- A61P13/12—Drugs for disorders of the urinary system of the kidneys
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
- A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/12—Drugs for disorders of the metabolism for electrolyte homeostasis
- A61P3/14—Drugs for disorders of the metabolism for electrolyte homeostasis for calcium homeostasis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P5/00—Drugs for disorders of the endocrine system
- A61P5/48—Drugs for disorders of the endocrine system of the pancreatic hormones
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
- A61K31/42—Oxazoles
- A61K31/424—Oxazoles condensed with heterocyclic ring systems, e.g. clavulanic acid
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
- A61K31/425—Thiazoles
- A61K31/429—Thiazoles condensed with heterocyclic ring systems
- A61K31/43—Compounds containing 4-thia-1-azabicyclo [3.2.0] heptane ring systems, i.e. compounds containing a ring system of the formula, e.g. penicillins, penems
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/496—Non-condensed piperazines containing further heterocyclic rings, e.g. rifampin, thiothixene or sparfloxacin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- Pharmacology & Pharmacy (AREA)
- Animal Behavior & Ethology (AREA)
- Epidemiology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Engineering & Computer Science (AREA)
- General Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Diabetes (AREA)
- Endocrinology (AREA)
- Hematology (AREA)
- Obesity (AREA)
- Molecular Biology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Cell Biology (AREA)
- Immunology (AREA)
- Urology & Nephrology (AREA)
- Emergency Medicine (AREA)
- Rheumatology (AREA)
- Gastroenterology & Hepatology (AREA)
- Pulmonology (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Peptides Or Proteins (AREA)
- Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
- Micro-Organisms Or Cultivation Processes Thereof (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201361831515P | 2013-06-05 | 2013-06-05 | |
| PCT/US2014/041063 WO2014197680A1 (en) | 2013-06-05 | 2014-06-05 | Vitamin d receptor agonists to treat diseases involving cxcl12 activity |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| MX2015016715A true MX2015016715A (es) | 2016-08-08 |
Family
ID=52008582
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| MX2015016715A MX2015016715A (es) | 2013-06-05 | 2014-06-05 | Agonistas del receptor de la vitamina d para tratar enfermedades que afectan a la actividad de cxcl12. |
Country Status (9)
| Country | Link |
|---|---|
| US (1) | US9895381B2 (enExample) |
| EP (2) | EP3473299A1 (enExample) |
| JP (1) | JP2016530219A (enExample) |
| CN (1) | CN105451818A (enExample) |
| AU (1) | AU2014274864B2 (enExample) |
| BR (1) | BR112015030518A2 (enExample) |
| CA (1) | CA2914487A1 (enExample) |
| MX (1) | MX2015016715A (enExample) |
| WO (1) | WO2014197680A1 (enExample) |
Families Citing this family (17)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| EP2988752A4 (en) | 2013-04-24 | 2017-01-18 | Salk Institute for Biological Studies | Vitamin d receptor/smad genomic circuit gates fibrotic response |
| US10953003B2 (en) | 2015-12-14 | 2021-03-23 | X4 Pharmaceuticals, Inc. | Methods for treating cancer |
| EP3389652B1 (en) | 2015-12-14 | 2022-09-28 | X4 Pharmaceuticals, Inc. | Methods for treating cancer |
| ES2935834T3 (es) | 2015-12-22 | 2023-03-10 | X4 Pharmaceuticals Inc | Métodos para tratar enfermedad de inmunodeficiencia |
| CA3019394A1 (en) * | 2016-04-08 | 2017-10-12 | X4 Pharmaceuticals, Inc. | Methods for treating cancer |
| CN106109476A (zh) * | 2016-06-13 | 2016-11-16 | 中山大学 | 骨化二醇作为吲哚胺2,3‑双加氧酶‑1抑制剂的用途 |
| CN109640988A (zh) | 2016-06-21 | 2019-04-16 | X4 制药有限公司 | Cxcr4抑制剂及其用途 |
| WO2017223243A1 (en) | 2016-06-21 | 2017-12-28 | X4 Pharmaceuticals, Inc. | Cxcr4 inhibitors and uses thereof |
| CN109562106B (zh) | 2016-06-21 | 2023-03-21 | X4 制药有限公司 | Cxcr4抑制剂及其用途 |
| WO2019023149A1 (en) | 2017-07-24 | 2019-01-31 | Salk Institute For Biological Studies | USE OF BROMODOMAIN-CONTAINING PROTEIN-9 ANTAGONISTS IN ASSOCIATION WITH VITAMIN D RECEPTOR AGONISTS IN THE TREATMENT OF DIABETES |
| US10548889B1 (en) | 2018-08-31 | 2020-02-04 | X4 Pharmaceuticals, Inc. | Compositions of CXCR4 inhibitors and methods of preparation and use |
| EP3851518A4 (en) * | 2018-09-10 | 2022-06-22 | Tokyo Institute of Technology | PROCESS FOR THE PRODUCTION OF COLON CELLS FROM PLURIPOTENTIC STEM CELLS |
| JP7377486B2 (ja) * | 2018-09-10 | 2023-11-10 | 国立大学法人東京工業大学 | 多能性幹細胞から腸細胞の作製方法 |
| JP2023513794A (ja) * | 2020-02-14 | 2023-04-03 | ソーク インスティテュート フォー バイオロジカル スタディーズ | Ｕｌｋ１／２の阻害剤およびその使用方法 |
| EP4117662A4 (en) | 2020-03-10 | 2024-04-03 | X4 Pharmaceuticals, Inc. | METHODS OF TREATING NEUTROPENIA |
| CN113350362A (zh) * | 2021-06-11 | 2021-09-07 | 扬州大学附属医院 | 维生素d受体激动剂在制备预防和/或治疗急性胰腺炎的药物中的应用 |
| EP4646211A1 (en) * | 2023-01-06 | 2025-11-12 | Adge Pharmaceuticals Inc. | Methods for treating metabolic syndrome |
Family Cites Families (25)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US6566353B2 (en) * | 1996-12-30 | 2003-05-20 | Bone Care International, Inc. | Method of treating malignancy associated hypercalcemia using active vitamin D analogues |
| AUPO727097A0 (en) * | 1997-06-10 | 1997-07-03 | Unisearch Limited | Method of treatment of hepatoma and pharmaceutical compositions for use therein |
| US6358939B1 (en) | 1999-12-21 | 2002-03-19 | Northern Lights Pharmaceuticals, Llc | Use of biologically active vitamin D compounds for the prevention and treatment of inflammatory bowel disease |
| US20030228689A1 (en) | 2002-05-31 | 2003-12-11 | Isis Pharmaceuticals Inc. | Antisense modulation of G protein-coupled receptor kinase 6 expression |
| RS20050106A (sr) | 2002-08-19 | 2007-11-15 | Pfizer Products Inc., | Kombinovana terapija hiperproliferativnih bolesti |
| WO2004047673A2 (en) | 2002-11-21 | 2004-06-10 | Novacea, Inc. | Treatment of liver disease with active vitamin d compounds |
| JP2007501864A (ja) | 2003-06-11 | 2007-02-01 | ノバセア インコーポレイティッド | 活性ビタミンｄ化合物単独または他の治療薬との併用による、免疫介在疾患の治療法 |
| US20050148557A1 (en) | 2003-07-29 | 2005-07-07 | Jin Tian | Use of Vitamin Ds to treat kidney disease |
| US20050124591A1 (en) | 2003-07-29 | 2005-06-09 | Jin Tian | Use of vitamin Ds to treat kidney disease |
| US20070275934A1 (en) * | 2004-05-10 | 2007-11-29 | Curd John G | Treatment of pancreatic cancer with active vitamin d compounds in combination with other treatments |
| WO2006032299A1 (en) | 2004-09-24 | 2006-03-30 | Susanna Miettinen | Use of inhibitors of 24-hydroxylase in the treatment of cancer |
| US20060135610A1 (en) | 2004-12-22 | 2006-06-22 | Bortz Jonathan D | Cardiovascular compositions |
| US8968806B2 (en) | 2005-04-26 | 2015-03-03 | Sean Joseph Delaney | Method and system for creating and using a supplement to balance animal diets |
| CA2661546A1 (en) | 2006-08-25 | 2008-02-28 | Cougar Biotechnology, Inc. | Methods for treating cancer comprising the administration of a vitamin d compound and an additional therapeutic agent, and compositions containing the same |
| TW200833345A (en) | 2006-11-01 | 2008-08-16 | Novacea Inc | Use of vitamin D compounds and mimics thereof to enhance delivery of therapeutics and oxygen to tumors and other tissues |
| US20100099640A1 (en) | 2007-05-04 | 2010-04-22 | Joannes Geuns | Tissue degeneration protection |
| US8318708B2 (en) * | 2007-11-06 | 2012-11-27 | Salk Institute For Biological Studies | Use of vitamin D receptor agonists, ligands, and precursors to treat pancreatic fibrosis |
| AU2008323903B2 (en) * | 2007-11-06 | 2013-12-05 | The Salk Institute For Biological Studies | Use of vitamin D receptor agonists and precursors to treat fibrosis |
| JP5993147B2 (ja) * | 2009-03-12 | 2016-09-14 | キーバイオサイエンス・アクチエンゲゼルシャフト | 糖尿病およびメタボリックシンドロームの治療 |
| PL388252A1 (pl) * | 2009-06-10 | 2010-12-20 | Instytut Farmaceutyczny | Terapia skojarzona raka jelita grubego |
| IT1397901B1 (it) * | 2010-01-26 | 2013-02-04 | Consiglio Nazionale Ricerche | Peptidi ciclici che legano il recettore cxcr4 e relativi usi in campo medico e diagnostico. |
| EP2569000B1 (en) * | 2010-05-13 | 2017-09-27 | Indiana University Research and Technology Corporation | Glucagon superfamily peptides exhibiting nuclear hormone receptor activity |
| WO2012127037A2 (en) | 2011-03-24 | 2012-09-27 | Leo Pharma A/S | A composition comprising lipid nanoparticles and a corticosteroid or vitamin d derivative |
| JP2013056834A (ja) | 2011-09-07 | 2013-03-28 | Okayama Univ | 線維化疾患治療剤 |
| CN102342914A (zh) | 2011-10-07 | 2012-02-08 | 南昌大学 | 卡泊三醇固体脂质纳米粒及其制备方法 |
-
2014
- 2014-06-05 CN CN201480043580.0A patent/CN105451818A/zh active Pending
- 2014-06-05 MX MX2015016715A patent/MX2015016715A/es unknown
- 2014-06-05 AU AU2014274864A patent/AU2014274864B2/en not_active Ceased
- 2014-06-05 EP EP18206167.1A patent/EP3473299A1/en not_active Withdrawn
- 2014-06-05 CA CA2914487A patent/CA2914487A1/en not_active Abandoned
- 2014-06-05 EP EP14806812.5A patent/EP3003486A4/en not_active Withdrawn
- 2014-06-05 BR BR112015030518A patent/BR112015030518A2/pt not_active IP Right Cessation
- 2014-06-05 WO PCT/US2014/041063 patent/WO2014197680A1/en not_active Ceased
- 2014-06-05 JP JP2016517990A patent/JP2016530219A/ja active Pending
-
2015
- 2015-12-04 US US14/959,105 patent/US9895381B2/en active Active
Also Published As
| Publication number | Publication date |
|---|---|
| EP3003486A1 (en) | 2016-04-13 |
| JP2016530219A (ja) | 2016-09-29 |
| EP3473299A1 (en) | 2019-04-24 |
| CN105451818A (zh) | 2016-03-30 |
| US9895381B2 (en) | 2018-02-20 |
| AU2014274864A1 (en) | 2016-01-21 |
| US20160089385A1 (en) | 2016-03-31 |
| AU2014274864B2 (en) | 2018-10-18 |
| BR112015030518A2 (pt) | 2017-08-29 |
| WO2014197680A1 (en) | 2014-12-11 |
| EP3003486A4 (en) | 2017-03-08 |
| CA2914487A1 (en) | 2014-12-11 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| MX2015016715A (es) | Agonistas del receptor de la vitamina d para tratar enfermedades que afectan a la actividad de cxcl12. | |
| MX369770B (es) | Compuestos agonistas triples de glucagón-glp-1-gip. | |
| PH12019501216A1 (en) | New compounds as peptidic trigonal glp1/glucagon/gip receptor agonists | |
| EA035466B9 (ru) | Соединения и способы на основе двойного агониста гип и гпп-1 | |
| MX362527B (es) | Combinacion farmaceutica para uso en el control glucemico en pacientes con diabetes de tipo 2. | |
| UA118558C2 (uk) | Пептидна сполука | |
| MD3242887T2 (ro) | Compuși co-agonişti ai GIP și GLP-1 | |
| MX2013013242A (es) | Combinacion farmaceutica para mejorar el control glucemico como terapia adicional a la insulina basal. | |
| MX2018000362A (es) | Derivados de exendina-4 como agonistas peptidicos duales selectivos de los receptores de glp-1/glucagon. | |
| MX2016013244A (es) | Derivados de exendina-4 como agonistas peptidicos duales del receptor de glp-1/glucagon. | |
| IN2014DN09782A (enExample) | ||
| PH12015500688A1 (en) | Exendin-4 derivatives as dual glp1/glucagon agonists | |
| MX342675B (es) | Formulaciones estables para inyeccion parenteral de farmacos de peptido. | |
| CL2014003421A1 (es) | Análogos de glucagón que exhiben actividad agonista en el receptor del péptido insulinotrópico dependiente de glusosa (gip): composición farmacéutica; y método para reducir el aumento de peso o inducir pérdida de peso, particularmente para el tratamiento de la obesidad. | |
| MX2019006427A (es) | Nuevos compuestos como agonistas peptidicos de receptores de glp1/glucagon/gip. | |
| EP4406593A3 (en) | Use of long-acting glp-1 peptides | |
| MX362190B (es) | Agonistas duales de glp1/gip o trigonales de glp1/gip/glucagon. | |
| MX2016013248A (es) | Agonistas duales del receptor de glp-1/glucagon derivados de exendina-4. | |
| MX365458B (es) | Agonistas de glucagon/peptido similiar al glucagon de tipo 1 (glp-1) para el tratamiento de la obesidad. | |
| MY207109A (en) | Use of agonists of formyl peptide receptor 2 for treating ocular inflammatory diseases | |
| MX2014015423A (es) | Analogos de peptido de exedina-4. | |
| MX2014005351A (es) | Conjugados de gastrina peptidicos de agonistas de receptor glp-1. | |
| MX381278B (es) | Composición para la estimulación ovárica controlada. | |
| GT201700224A (es) | Proteína de unión a rgma y su uso | |
| HK1223825A1 (zh) | 包含阿曲生坦的稳定化药物剂型 |